Neurocrine Biosciences, Inc.

Neurocrine Biosciences, Inc.'s next confirmed earnings release is scheduled for November 2, 2026.

As of June 30, 2026, Neurocrine Biosciences, Inc. has 101.60M shares outstanding.

As of June 30, 2026, Neurocrine Biosciences, Inc. maintains a current ratio of 1.87, meaning it holds 1.9x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 10.88, indicating elevated leverage, while an interest coverage ratio of 290.38 demonstrates strong ability to service its debt obligations.

Over the twelve months ended June 30, 2026, Neurocrine Biosciences, Inc. posted a return on equity (ROE) of 22.09, showing how much profit the company earns on every dollar of shareholder capital. Return on invested capital (ROIC) comes in at 16.19 - the clearest signal of whether the business earns more on its capital than that capital costs, and the core measure of a durable competitive advantage. Return on assets (ROA) stands at 15.26, measuring how efficiently the asset base is converted into earnings. Return on capital employed (ROCE) is 19.58, useful for judging operating efficiency across full business cycles. The company generates approximately 1.40M in revenue per employee across its workforce of 1,950.00, a quick read on workforce productivity versus industry peers. Inventory turnover of 0.85 indicates how many times Neurocrine Biosciences, Inc. sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended June 30, 2026, Neurocrine Biosciences, Inc. recorded 189.60M in income tax expense. That works out to an effective tax rate of 24.96, which can sit above or below the statutory corporate tax rate depending on foreign earnings mix, tax credits, and one-off items. Taxes are levied on pretax income of 759.52M, leaving 569.92M in net income after tax - the gap is what shifts in the tax rate do to reported earnings and EPS.

As of the close on October 13, 2026, Neurocrine Biosciences, Inc.'s stock has gained approximately 31.13% over the past 52 weeks.

Over the twelve months ended June 30, 2026, Neurocrine Biosciences, Inc. generated 2.73B in revenue and converted that into 569.92M in net income, yielding earnings per share of 5.51. EBITDA reached 680.27M, while operating income came in at 651.27M.

As of June 30, 2026, Neurocrine Biosciences, Inc. holds 314.89M in cash and equivalents against 324.59M in total debt, resulting in a net debt position of -268.52M. Total book value stands at 2.98B, with working capital of 616.37M providing operational flexibility.

Neurocrine Biosciences, Inc. produced 725.51M in operating cash flow over the twelve months ended June 30, 2026.

Over the twelve months ended June 30, 2026, Neurocrine Biosciences, Inc. posted a gross margin of 97.97, reflecting its pricing power and cost economics. The operating margin of 23.90 and net profit margin of 20.91 provide insight into operational efficiency.